Suppr超能文献

[糖皮质激素与骨骼。双膦酸盐治疗糖皮质激素性骨质疏松症的疗效与安全性]

[Glucocorticoid and Bone. Efficacy and safety of bisphosphonate in treatment of glucocorticoid induced osteoporosis].

作者信息

Tanaka Ikuko

机构信息

Initiative for Rheumatology & Osteoporosis, Nagoya Rheumatology Clinic, Japan.

出版信息

Clin Calcium. 2014 Sep;24(9):1371-8.

Abstract

Glucocorticoids (GCs) were widely used for the treatment of various disorders. And Osteoporosis is one of the major complications of glucocorticoid therapy. An increased risk of both vertebral and nonvertebral fractures has been reported with dosages of prednisolone or equivalent as low as 2.5-7.5 mg daily. The skeletal effects of glucocorticoids include both direct and indirect actions on bone that result in an early, transient increase in bone resorption accompanied by a decrease in bone formation, which is maintained for the duration of glucocorticoid therapy. Bisphosphonates are the front-line choice for prevention of fracture in glucocorticoid-treated patients and are recommended renewal GIOP guideline from Japan.

摘要

糖皮质激素(GCs)被广泛用于治疗各种疾病。骨质疏松症是糖皮质激素治疗的主要并发症之一。据报道,每日服用低至2.5 - 7.5毫克泼尼松龙或等效药物时,椎体和非椎体骨折的风险都会增加。糖皮质激素对骨骼的影响包括对骨骼的直接和间接作用,导致骨吸收早期短暂增加,同时骨形成减少,这种情况在糖皮质激素治疗期间持续存在。双膦酸盐是糖皮质激素治疗患者预防骨折的一线选择,并且被日本更新的糖皮质激素诱导的骨质疏松症(GIOP)指南所推荐。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验